| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 21043 |
| Drug | Nivolumab |
| Brand | Opdivo® |
| Indication | Nivolumab as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. |
| Assessment Process | |
| Rapid review commissioned | 21/09/2021 |
| Rapid review completed | 20/10/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 28/10/2021 |
| Pre-submission consultation with Applicant | 20/12/2021 |
| Full submission received from Applicant | 11/05/2022 |
| Preliminary review sent to Applicant | 24/10/2022 |
| NCPE assessment re-commenced | 21/11/2022 |
| Factual accuracy sent to Applicant | 23/01/2023 |
| NCPE assessment re-commenced | 30/01/2023 |
| NCPE assessment completed | 13/02/2023 |
| NCPE assessment outcome | The NCPE recommends that nivolumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. September 2023
